Presentación nucleo uct 2012 ii
-
Upload
jorge-parodi -
Category
Business
-
view
228 -
download
3
Transcript of Presentación nucleo uct 2012 ii
![Page 1: Presentación nucleo uct 2012 ii](https://reader035.fdocument.pub/reader035/viewer/2022062307/55852054d8b42a4c128b4a60/html5/thumbnails/1.jpg)
Plantas medicinales y terapias alternativas en Alzheimer. Una tierra desconocida
Laboratorio de Fisiología de la Reproducción
Jorge [email protected]
![Page 2: Presentación nucleo uct 2012 ii](https://reader035.fdocument.pub/reader035/viewer/2022062307/55852054d8b42a4c128b4a60/html5/thumbnails/2.jpg)
![Page 3: Presentación nucleo uct 2012 ii](https://reader035.fdocument.pub/reader035/viewer/2022062307/55852054d8b42a4c128b4a60/html5/thumbnails/3.jpg)
![Page 4: Presentación nucleo uct 2012 ii](https://reader035.fdocument.pub/reader035/viewer/2022062307/55852054d8b42a4c128b4a60/html5/thumbnails/4.jpg)
![Page 5: Presentación nucleo uct 2012 ii](https://reader035.fdocument.pub/reader035/viewer/2022062307/55852054d8b42a4c128b4a60/html5/thumbnails/5.jpg)
http://www.alz.org/alzheimers_disease_alternative_treatments.asp
Caprylic acid and coconut oil ConcernsCoenzyme Q10Coral calciumGinkgo bilobaHuperzine AOmega-3 fatty acidsPhosphatidylserineTramiprosate
![Page 6: Presentación nucleo uct 2012 ii](https://reader035.fdocument.pub/reader035/viewer/2022062307/55852054d8b42a4c128b4a60/html5/thumbnails/6.jpg)
Conclusion Compared with placebo, the use of G biloba, 120 mg twice daily, did not result in less cognitive decline in older adults with normal cognition or with mild cognitive impairment.
Snitz et al 2009 JAMA
Test Placebo Ginko
Memory 0,15 0,14
Executive test 3,27 3,47
![Page 7: Presentación nucleo uct 2012 ii](https://reader035.fdocument.pub/reader035/viewer/2022062307/55852054d8b42a4c128b4a60/html5/thumbnails/7.jpg)
Date of download: 7/14/2012Copyright © 2012 American Medical Association.
All rights reserved.
From: Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease: A Randomized Trial
JAMA. 2010;304(17):1903-1911. doi:10.1001/jama.2010.1510
![Page 8: Presentación nucleo uct 2012 ii](https://reader035.fdocument.pub/reader035/viewer/2022062307/55852054d8b42a4c128b4a60/html5/thumbnails/8.jpg)
Danitz and Parsons 2008 IJNP
Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease
Conclusions In patients with moderate or severe Alzheimer's disease, continued treatment with donepezil was associated with cognitive benefits that exceeded the minimum clinically important difference and with significant functional benefits over the course of 12 months JAMA 2012
![Page 9: Presentación nucleo uct 2012 ii](https://reader035.fdocument.pub/reader035/viewer/2022062307/55852054d8b42a4c128b4a60/html5/thumbnails/9.jpg)
Palmer 2002 Trends in Phar
![Page 10: Presentación nucleo uct 2012 ii](https://reader035.fdocument.pub/reader035/viewer/2022062307/55852054d8b42a4c128b4a60/html5/thumbnails/10.jpg)
Benilova et al 2012 Nature Neuroscience
![Page 11: Presentación nucleo uct 2012 ii](https://reader035.fdocument.pub/reader035/viewer/2022062307/55852054d8b42a4c128b4a60/html5/thumbnails/11.jpg)
![Page 12: Presentación nucleo uct 2012 ii](https://reader035.fdocument.pub/reader035/viewer/2022062307/55852054d8b42a4c128b4a60/html5/thumbnails/12.jpg)
Agregados Ab1-40 se localizan en regiones sinápticas
Ab – DAC (1:2)24 horas0.5 mM
MAP1B – Cy3 A
Ab - DAC B
SV2 – Cy5 C G
H
10 mm
D
H
G
![Page 13: Presentación nucleo uct 2012 ii](https://reader035.fdocument.pub/reader035/viewer/2022062307/55852054d8b42a4c128b4a60/html5/thumbnails/13.jpg)
Parodi et al (2010) JBC
![Page 14: Presentación nucleo uct 2012 ii](https://reader035.fdocument.pub/reader035/viewer/2022062307/55852054d8b42a4c128b4a60/html5/thumbnails/14.jpg)
![Page 15: Presentación nucleo uct 2012 ii](https://reader035.fdocument.pub/reader035/viewer/2022062307/55852054d8b42a4c128b4a60/html5/thumbnails/15.jpg)
![Page 16: Presentación nucleo uct 2012 ii](https://reader035.fdocument.pub/reader035/viewer/2022062307/55852054d8b42a4c128b4a60/html5/thumbnails/16.jpg)
Savonenko et al (2005) Neurobiology of Disease
![Page 17: Presentación nucleo uct 2012 ii](https://reader035.fdocument.pub/reader035/viewer/2022062307/55852054d8b42a4c128b4a60/html5/thumbnails/17.jpg)
Dinamarca et al (2006) Molecular Psychiatry
![Page 18: Presentación nucleo uct 2012 ii](https://reader035.fdocument.pub/reader035/viewer/2022062307/55852054d8b42a4c128b4a60/html5/thumbnails/18.jpg)
Inestrosa et al (2011) Translation Psychiatry
![Page 19: Presentación nucleo uct 2012 ii](https://reader035.fdocument.pub/reader035/viewer/2022062307/55852054d8b42a4c128b4a60/html5/thumbnails/19.jpg)
Montesinos et al (2012) in report
![Page 20: Presentación nucleo uct 2012 ii](https://reader035.fdocument.pub/reader035/viewer/2022062307/55852054d8b42a4c128b4a60/html5/thumbnails/20.jpg)
Modeling
0 50 100 150 200
0,0
0,2
0,4
0,6
0,8
1,0
1,2
Tiempo (min)
Tu
rbim
etri
a (D
.O. 4
05 n
m)
Control 5 mM Etanol 10 mM Etanol 50 mM EtanolA B
C D E
Ormeño et al (2012) in review
![Page 21: Presentación nucleo uct 2012 ii](https://reader035.fdocument.pub/reader035/viewer/2022062307/55852054d8b42a4c128b4a60/html5/thumbnails/21.jpg)
![Page 22: Presentación nucleo uct 2012 ii](https://reader035.fdocument.pub/reader035/viewer/2022062307/55852054d8b42a4c128b4a60/html5/thumbnails/22.jpg)
C
BA
D
![Page 23: Presentación nucleo uct 2012 ii](https://reader035.fdocument.pub/reader035/viewer/2022062307/55852054d8b42a4c128b4a60/html5/thumbnails/23.jpg)
A
ASP-23
LYS-28
B
ASP-23
LYS-28
2.7Ẳ
ASP-23
LYS-28C
12.7Ẳ
D
ASP-23
LYS-28
6.3Ẳ
![Page 24: Presentación nucleo uct 2012 ii](https://reader035.fdocument.pub/reader035/viewer/2022062307/55852054d8b42a4c128b4a60/html5/thumbnails/24.jpg)
0,0 0,5 1,0 1,5 2,0 2,50
2
4
6
8
10
12
Time (ns)
Control Ethanol 10 %
A
0,0 0,5 1,0 1,5 2,0 2,5
0
5
10
15
20
25 Control Ethanol 1%
Dev
iation (R
MSD
) Time (ns)
B
Ẳ
![Page 25: Presentación nucleo uct 2012 ii](https://reader035.fdocument.pub/reader035/viewer/2022062307/55852054d8b42a4c128b4a60/html5/thumbnails/25.jpg)
Control
Trata
das 1 5 10 25 50 100
0,0
0,5
1,0
1,5
2,0
2,5
*
*
**
Etanol (mM)
Agregados amilodes
Fre
cuen
cia
(Hz)
Act
ivid
ad S
ináp
tica
Esp
on
tán
ea
Control
Agregados A 0.5 M (24 h)
Agregados A 0.5 M + 10 mM Etanol (24 h)
Agregados A 0.5 M + 50 mM Etanol (24 h)
50 mM Etanol (24 h)
0.2 s 20 p
A
0.2 s 20 p
A
0.2 s 20 p
A0.2 s 20
pA
0.2 s 20 p
A
Sv2
Control
Aaggregates 0.5 M
Aβ aggregates 5 M
Aβ aggregates 10 M
10 mM etanol
50 mM etanol
Aaggregates 0.5 M
Ormeño et al (2012) in review
![Page 26: Presentación nucleo uct 2012 ii](https://reader035.fdocument.pub/reader035/viewer/2022062307/55852054d8b42a4c128b4a60/html5/thumbnails/26.jpg)
![Page 27: Presentación nucleo uct 2012 ii](https://reader035.fdocument.pub/reader035/viewer/2022062307/55852054d8b42a4c128b4a60/html5/thumbnails/27.jpg)
-6 -5 -4 -3 -2 -1 0 10,0
0,5
1,0
1,5
Num
ber
of events
Amplitude (nA)
Control Gramicidin Amphotericin B Aggregate
A B C
-200 -150 -100 -50 0 50 100
-8
-6
-4
-2
0
2
4
6
8
nA
mV
Aggregate Gramicidin Amphotericin Control
Contro
l
Gramicidin
Amph
otericin B
Aggr
egates
0
-200
-400
-600
-800
-1000
**
Mem
bra
ne c
onducta
nces (nS
)
*
Parodi et al (2012) in review
![Page 28: Presentación nucleo uct 2012 ii](https://reader035.fdocument.pub/reader035/viewer/2022062307/55852054d8b42a4c128b4a60/html5/thumbnails/28.jpg)
B
C
A
D
+ 20 mV0 mV
Control
Aggregate
High Ca2+
NR
High Ca2+
NR
-100 mV
+ 20 mV0 mV
-100 mV
100 nA250 ms
4 min
200
nA
Rabbit serum
15 min Aggregate
0 min 15 min
NR
0
50
100
150
200
250
300
Aggregate
High Ca2+NR
*
*
Curr
ent a
mplit
ude
(% o
f co
ntr
ol a
t +20
mV)
*
NR High Ca2+
0
50
100
150
200
15 min Aggregate15 min
*
Curr
ent am
plit
ude
(% o
f co
ntr
ol ) NR
0 min
![Page 29: Presentación nucleo uct 2012 ii](https://reader035.fdocument.pub/reader035/viewer/2022062307/55852054d8b42a4c128b4a60/html5/thumbnails/29.jpg)
20
0 n
A
60 s
100 μM ATP0 min 15 min
15 min AggregateNR
0
20
40
60
80
100
120
15 min Aggregate15 min
Cu
rre
nt
(% o
f c
on
tro
l)
0 min
*
![Page 30: Presentación nucleo uct 2012 ii](https://reader035.fdocument.pub/reader035/viewer/2022062307/55852054d8b42a4c128b4a60/html5/thumbnails/30.jpg)
![Page 31: Presentación nucleo uct 2012 ii](https://reader035.fdocument.pub/reader035/viewer/2022062307/55852054d8b42a4c128b4a60/html5/thumbnails/31.jpg)
AgradecimientosDr. Luis AguayoDr. Nibaldo InestrosaFernando SepulvedaDavid Ormeño
Laboratorio de Fisiología de la ReproducciónFelipeGuillermoDaniela
ColaboradoresDr. Alexander OrtloffMsC Patricio Peña